Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey

Yildiz I., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., ...Daha Fazla

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.41, sa.12, ss.1380-1387, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 12
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1093/jjco/hyr151
  • Dergi Adı: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1380-1387
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma.